You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

TYK2 inhibitor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Cicatricial Alopecia Trial in New York (PF-06700841, Placebo)

Recruiting
  • Cicatricial Alopecia
  • New York, New York
    Icahn School of Medicine at Mount Sinai
Aug 16, 2022

Metastatic Colorectal Cancer Trial (LB-100, Azenosertib)

Not yet recruiting
  • Metastatic Colorectal Cancer
  • (no location specified)
Oct 31, 2023

Metastatic Microsatellite-stable Colorectal Cancer Trial (LB-100, Atezolizumab)

Not yet recruiting
  • Metastatic Microsatellite-stable Colorectal Cancer
  • (no location specified)
Sep 1, 2023

Diabetes, Cellular Senescence, Sodium-Glucose Transporter 2 Inhibitors Trial in Seoul (SGLT2 inhibitor, Glimepiride)

Not yet recruiting
  • Diabetes Mellitus
  • +2 more
  • Seoul, Korea, Republic of
    Yonsei University College of Medicine
Aug 1, 2023

Ketoses, Metabolic Trial (SGLT2 inhibitor + low-carb diet, + low-carb diet)

Not yet recruiting
  • Ketoses, Metabolic
  • SGLT2 inhibitor + low-carb diet
  • placebo + low-carb diet
  • (no location specified)
Dec 28, 2022

Estrogen-receptor-positive Breast Cancer, HER2/Neu-Negative Breast Cancer, Advanced Breast Cancerv Trial in Chicago

Not yet recruiting
  • Estrogen-receptor-positive Breast Cancer
  • +3 more
  • elacestrant, palbociclib, abemaciclib, ribociclib
  • Chicago, Illinois
    Northwestern University
Sep 25, 2023

Breast Cancer Trial in Guangzhou (Capecitabine, Aromatase Inhibitor)

Active, not recruiting
  • Breast Cancer
  • Guangzhou, Guangdong, China
    State Key Laboratory of Oncology in South China, Sun Yat-sen Uni
Jan 27, 2023

Breast Cancer Metastatic Cancer Trial in Shanghai (Fluzoparib, Dalpiciclib, Fulvestrant/AI)

Recruiting
  • Breast Cancer Metastatic Cancer
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Feb 26, 2023

Lupus Nephritis, Chronic Kidney Diseases Trial in Hong Kong (Dapagliflozin 10mg Tab, Standard maintenance therapy)

Not yet recruiting
  • Lupus Nephritis
  • Chronic Kidney Diseases
  • Dapagliflozin 10mg Tab
  • Standard maintenance therapy
  • Hong Kong, Hong Kong
    Queen Mary Hospital
Nov 24, 2023

Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Radiotherapy, PD-1/PD-L1 inhibitor, Granulocyte-macrophage

Recruiting
  • Advanced Solid Tumor
  • Refractory Tumor
  • Radiotherapy
  • +4 more
  • Suzhou, China
    The Second Affiliated Hospital of SchoowUniversity
Sep 14, 2023

Metastatic Breast Cancer Trial in Herlev, Vejle (PARP inhibitor 2X-121)

Active, not recruiting
  • Metastatic Breast Cancer
  • PARP inhibitor 2X-121
  • Herlev, Denmark
  • +1 more
Feb 1, 2023

Breast Cancer Trial in Marseille (M1774, Fulvestrant injection)

Not yet recruiting
  • Breast Cancer
  • Marseille, France
    Institut Paoli Calmettes
Aug 9, 2023

Cardiorenal Syndrome Trial in New Haven (Dapagliflozin)

Not yet recruiting
  • Cardiorenal Syndrome
  • New Haven, Connecticut
    Yale New Haven Hospital
Oct 26, 2023

Cystic Fibrosis-related Diabetes, Cystic Fibrosis Trial in Minneapolis (Empagliflozin, Placebo Control)

Not yet recruiting
  • Cystic Fibrosis-related Diabetes
  • Cystic Fibrosis
  • Minneapolis, Minnesota
    University of Minnesota
Nov 20, 2023

Compare Overall Survival in Medicare Metastatic Breast Cancer

Active, not recruiting
  • Breast Cancer
  • New York, New York
    Pfizer New York
Oct 11, 2023

Dermatomyositis Trial in Orlando, Plantation (Brepocitinib, Placebo)

Recruiting
  • Dermatomyositis
  • Orlando, Florida
  • +1 more
Jun 24, 2022

Relapsed or Refractory Lymphoma Trial in Miami (Itraconazole 200 mg, Fluconazole 400 mg, Rifampin 600 mg)

Completed
  • Relapsed or Refractory Lymphoma
  • Itraconazole 200 mg
  • +3 more
  • Miami, Florida
    QPS- Miami
Jan 12, 2023

Gastrointestinal Tumor Trial in Hangzhou (Water-filtered infrared A radiation whole-body hyperthermia (HECKEL 3000MT-4T,

Completed
  • Gastrointestinal Tumor
  • Water-filtered infrared A radiation whole-body hyperthermia (HECKEL 3000MT-4T, Germany)
  • tislelizumab (BeiGene, China) combined with PD-1 inhibitor
  • Hangzhou, China
    Zhejiang Hospital
Sep 1, 2023

Severe Aplastic Anemia, Single Lineage Cytopenias, T-LGL, Hypoplastic MDS Trial run by the National Heart, Lung, and Blood

Not yet recruiting
  • Severe Aplastic Anemia
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 23, 2023

Healthy Adults Trial in Dallas (Treatment A, Treatment B)

Not yet recruiting
  • Healthy Adults
  • Treatment A
  • Treatment B
  • Dallas, Texas
    Labcorp Clinical Research Unit Inc
May 11, 2023

Novel Antidiabetic Drug Combined With Angiotensin

Recruiting
  • Type 2 Diabetes
  • Antidiabetic Drugs
    • Beijing, Beijing, China
    • +1 more
    Jun 20, 2023

    Cyclin-dependent Kinase Inhibitor 2A on Labor-related Signals

    Not yet recruiting
    • Preterm Labor
      • (no location specified)
      May 9, 2023

      Heart Failure With Reduced Ejection Fraction Trial in Porto (Sacubitril-valsartan, SGLT2 inhibitor)

      Recruiting
      • Heart Failure With Reduced Ejection Fraction
      • Porto, Portugal
      • +3 more
      Aug 9, 2023

      Advanced Solid Tumor Trial in Beijing (Inosine 0.2g orally 3 times/day, PD-1/PD-L1 inhibitor ,chemo/targeting)

      Completed
      • Advanced Solid Tumor
      • Inosine 0.2g orally 3 times/day
      • PD-1/PD-L1 inhibitor ,chemotherapy/targeting
      • Beijing, Beijing, China
        Qin li
      Mar 30, 2023

      Head Neck Cancer, Intratumoral Injection Trial in Chicago (RiMO-301)

      Recruiting
      • Head Neck Cancer
      • Intratumoral Injection
      • Chicago, Illinois
        University of Illinois at Chicago
      Apr 28, 2023